Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44132   clinical trials with a EudraCT protocol, of which   7324   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-003984-12
    Sponsor's Protocol Code Number:TP0001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-01-13
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-003984-12
    A.3Full title of the trial
    A MULTICENTER, OPEN-LABEL, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
    ESTUDIO MULTICÉNTRICO, ABIERTO Y DE ADMINISTRACIÓN REPETIDA, PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA EFICACIA DE UCB7665 EN SUJETOS CON TROMBOCITOPENIA INMUNE PRIMARIA
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to test the safety of UCB7665 in patients with low levels of platelets.
    Estudio para evaluar la seguridad de UCB7665 en pacientes con bajo nivel de plaquetas.
    A.4.1Sponsor's protocol code numberTP0001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUCB Biopharma SPRL
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUCB Biopharma SPRL
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUCB Biosciences GmbH
    B.5.2Functional name of contact pointClin Trial Reg & Results Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressAlfred-Nobel-Str. 10
    B.5.3.2Town/ cityMonheim
    B.5.3.3Post code40789
    B.5.3.4CountryGermany
    B.5.4Telephone number+34913913443
    B.5.5Fax number+492173481572
    B.5.6E-mailclinicaltrials@ucb.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameUCB7665
    D.3.2Product code UCB7665
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNUCB7665
    D.3.9.1CAS number 1584645-37-3
    D.3.9.2Current sponsor codeUCB7665
    D.3.9.3Other descriptive nameUCB7665
    D.3.9.4EV Substance CodeSUB166282
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary immune thrombocytopenia (ITP)
    Trombocitopenia Inmune Primaria (TPI)
    E.1.1.1Medical condition in easily understood language
    Primary immune thrombocytopenia (ITP)
    Trombocitopenia Inmune Primaria (TPI)
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level PT
    E.1.2Classification code 10043554
    E.1.2Term Thrombocytopenia
    E.1.2System Organ Class 10005329 - Blood and lymphatic system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and tolerability of UCB7665 administered by subcutaneous (sc) infusion in patients with immune thrombocytopenia (ITP)
    Evaluar la seguridad y la tolerabilidad del UCB7665 administrado en infusión s.c. a pacientes con TPI
    E.2.2Secondary objectives of the trial
    To assess the clinical efficacy of UCB7665 as measured by the change in platelet count
    To assess the pharmacodynamic (PD) effect of UCB7665 as measured by the change in total immunoglobulin G (IgG) concentration in blood
    Evaluar la eficacia clínica del UCB7665 en su medición mediante la variación de la cifra de plaquetas
    Evaluar el efecto farmacodinámico del UCB7665 en su medición mediante la variación de la concentración sanguínea de IgG total
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Subject has a diagnosis of primary immune thrombocytopenia for a minimum of 3 months prior to Screening Visit
    -Subject has a platelet count <30x10^9/L at Screening and <35x10^9/L at Baseline (Visit 2)
    -Subject has a current or history of a peripheral blood smear consistent with ITP
    -Subject has adequate peripheral venous access
    -Subject has responded to previous ITP therapy (according to the judgment of the investigator)
    -Se ha diagnosticado al sujeto TPI primaria como mínimo 3 meses antes de la Visita de Selección.
    -El sujeto presenta una cifra de plaquetas <30 × 10^9/L en la Selección y <35x10^9/L en la Visita Basal (Visita 2).
    -El sujeto presenta en la actualidad o ha presentado en el pasado una extensión de sangre periférica compatible con TPI
    -El sujeto cuenta con un acceso venoso periférico adecuado.
    -El sujeto ha respondido al tratamiento previo de la TPI (a juicio del investigador).
    E.4Principal exclusion criteria
    -Subject has an immunoglobulin G (IgG) level < = 6g/L at Screening Visit
    -Subject has a partial thromboplastin time (PTT) > =1.5x upper limit of normal (ULN) or International Normalized Ratio (INR)> =1.5 at Screening Visit
    -Subject has renal and/or liver impairment
    -Subject has planned an elective surgical procedure in the coming 6 months
    -Subject has evidence of a secondary cause of immune thrombocytopenia
    -Subject has a history of clinically relevant ongoing chronic infections
    -Subject has a family history of primary immunodeficiency
    -Subject has a clinically relevant active infection or has had a serious infection within 6 weeks prior to the first dose of IMP
    -Subject has a history of known inflammatory bowel disease, diverticular disease, and gastric or esophageal ulceration
    -Subject has experienced gastrointestinal bleed in the last 6 months prior to Screening Visit and/or has current gastritis or esophagitis
    -Subject has a medical history of thrombosis
    -Subject has a history of coagulopathy disorders
    -Subject has received a live vaccination within 8 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of IMP
    -Subject has had prior treatment with rituximab in the 6 months prior to the Baseline
    -Subject has not completed the washout period for the immune suppressants, biologics and other therapies
    -El sujeto presenta una concentración de IgG < = 6 g/L en la Visita de Selección.
    -El sujeto presenta un tiempo de tromboplastina parcial (TTP) > =1,5 veces el límite superior de la normalidad (LSN) o un índice internacional normalizado (INR) > =1,5 en la Visita de Selección.
    -El sujeto presenta insuficiencia renal o hepática.
    -El sujeto tiene prevista una intervención quirúrgica programada en los próximos 6 meses.
    -El sujeto tiene indicios de una causa secundaria de trombocitopenia inmune.
    -El sujeto tiene antecedentes de infecciones crónicas en curso de importancia clínica.
    -El sujeto tiene antecedentes familiares de inmunodeficiencia primaria.
    -El sujeto presenta una infección activa de importancia clínica o ha presentado una infección grave en el plazo de las 6 semanas anteriores a la primera administración del MI.
    -El sujeto tiene antecedentes de enfermedad intestinal inflamatoria, enfermedad diverticular o úlcera gástrica o esofágica.
    -El sujeto ha sufrido una hemorragia gastrointestinal en los últimos 6 meses antes de la Visita de Selección y/o presenta en la actualidad gastritis o esofagitis.
    -El sujeto tiene antecedentes de trombosis.
    -El sujeto tiene antecedentes de coagulopatía.
    -El sujeto ha recibido una vacuna de microorganismos vivos en el plazo de las 8 semanas anteriores a la Visita Basal; o tiene intención de recibir una vacuna de microorganismos vivos en el transcurso del estudio o en el plazo de las 7 semanas siguientes a la última administración del MI.
    -El sujeto ha recibido tratamiento previo con rituximab en los 6 meses anteriores a la Visita Basal.
    -El sujeto no ha completado el periodo de lavado de inmunosupresores, productos biológicos u otros tratamientos
    E.5 End points
    E.5.1Primary end point(s)
    Number of Subjects experiencing at least one Treatment Emergent Adverse Event (TEAE)
    Número de sujetos que experiementan al menos un Acontecimiento Adverso Surgido en el Tratamiento (AAST)
    E.5.1.1Timepoint(s) of evaluation of this end point
    From Visit2 (Week1) until End of Study Visit
    Desde la Visita 2 (Semana 1) hasta la Visita de Fin de Estudio
    E.5.2Secondary end point(s)
    -
    E.5.2.1Timepoint(s) of evaluation of this end point
    -
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Tolerabilidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Diferente dosis del mismo producto
    Different dose of the same product
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Czech Republic
    France
    Germany
    Italy
    Moldova, Republic of
    Poland
    Romania
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Subject Last Visit
    Última Visita del Último Sujeto
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 20
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 25
    F.4.2.2In the whole clinical trial 30
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No post-trial medication will be provided.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-02-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-02-04
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-02-04
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA